Agreement with Health House for distribution
of Satipharm CBD Gelpell® Capsules throughout Australia, New
Zealand and Asia.
VANCOUVER, March 28, 2019 /CNW/ - Harvest One Cannabis
Inc. ("Harvest One" or the "Company") (TSXV: HVT; OTCQX: HRVOF),
through it's wholly-owned subsidiary Satipharm Ltd. ("Satipharm")
today announced that it has entered into an agreement to become a
supplier to the renowned medicinal cannabis wholesale &
distribution business, Health House International Pty Ltd ("Health
House").
Under the terms of the agreement, Harvest One will supply Health
House with Satipharm CBD 50mg Gelpell® capsules. The product will
continue its availability in Australia, while expanding distribution to
New Zealand and Asia where and when legal.
Under the agreement, Health House distribute Satipharm's
medicinal cannabis products to their existing network of pharmacies
while also supporting healthcare professionals with Satipharm
product information. Health House International are one of the
major wholesalers to Australian pharmacies for medicinal cannabis.
In May 2017 they imported one of the
first legal international medicinal cannabis shipments into
Australia.
"This agreement with Health House increases the availability of
our Satipharm CBD 50mg Gelpell® capsules across Australia, while expanding Satipharm's medical
cannabis distribution territories to New
Zealand and Asia where and
when legal" said Grant Froese, CEO
of Harvest One. "We are committed to delivering the highest quality
cannabinoid-based products globally. As further regions become
available, we will endeavor to put agreements in place that will
allow us to meet the needs of our patients."
Pharmacist, CEO and founder of Health House Paul Mavor said:
"The addition of Satipharm's 50mg Gelpell® capsules to our range
allows us to provide clinically proven, high quality CBD to
customers. The capsule is a pharmaceutically elegant and convenient
dosage form for those who have been prescribed CBD."
ABOUT HARVEST ONE CANNABIS INC.
Harvest One is a global cannabis company that develops and
provides innovative lifestyle and wellness products to consumers
and patients in regulated markets around the world. The Company's
range of lifestyle solutions is designed to enhance quality of
life. Shareholders have significant exposure to the entire cannabis
value chain through three wholly-owned subsidiaries: United
Greeneries, a Licensed Producer; Satipharm (medical and
nutraceutical); and Dream Water Global (consumer), and a minority
interest in Burb Cannabis (retail operations). For more
information, please visit www.harvestone.com.
About Satipharm
Satipharm is a health and wellness company which is specialised
in the development and manufacture of cannabinoid-based products
from the cannabis plant. Our mission is to deliver the highest
quality products that are designed specifically with the needs of
our customers in mind.
About Health House
Health House International was the first medical cannabis
importer into Australia and
currently wholesales to pharmacies and researchers around the
country. They have a team of pharmacists that can counsel
prescribers on strengths, dosage, side effects and interactions.
They offer a next business day delivery service for their range of
medical cannabis products for authorised patients.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words "could",
"intend", "expect", "believe", "will", "projected", "estimated" and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on the Company's current belief or
assumptions as to the outcome and timing of such future events.
Actual future results may differ materially. The forward-looking
information contained in this press release is made as of the date
hereof, and the Company is not obligated to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue
reliance on forward-looking information. The foregoing statements
expressly qualify any forward-looking information contained
herein.
Neither TSX-V nor its Regulation Services Provider (as that term
is defined in the policies of the TSX-V) accept responsibility for
the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/harvest-one-announces-new-satipharm-distribution-agreement-300819958.html
SOURCE Harvest One Cannabis Inc.